The Role of the PAX8/PPARγ Fusion Oncogene in Thyroid Cancer
Thyroid cancer is uncommon and exhibits relatively low mortality rates. However, a subset of patients experience inexorable growth, metastatic spread, and mortality. Unfortunately, for these patients, there have been few significant advances in treatment during the last 50 years. While substantial a...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2008-01-01
|
| Series: | PPAR Research |
| Online Access: | http://dx.doi.org/10.1155/2008/672829 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548515829514240 |
|---|---|
| author | Kimberly A. Placzkowski Honey V. Reddi Stefan K. G. Grebe Norman L. Eberhardt Bryan McIver |
| author_facet | Kimberly A. Placzkowski Honey V. Reddi Stefan K. G. Grebe Norman L. Eberhardt Bryan McIver |
| author_sort | Kimberly A. Placzkowski |
| collection | DOAJ |
| description | Thyroid cancer is uncommon and exhibits relatively low mortality rates. However, a subset of patients experience inexorable growth, metastatic spread, and mortality. Unfortunately, for these patients, there have been few significant advances in treatment during the last 50 years. While substantial advances have been made in recent years about the molecular genetic events underlying papillary thyroid cancer, the more aggressive follicular thyroid cancer remains poorly understood. The recent discovery of the PAX8/PPARγ translocation in follicular thyroid carcinoma has promoted progress in the role of PPARγ as a tumor suppressor and potential therapeutic target. The PAX8/PPARγ fusion gene appears to be an oncogene. It is most often expressed in follicular carcinomas and exerts a dominant-negative effect on wild-type PPARγ, and stimulates transcription of PAX8-responsive promoters. PPARγ agonists have shown promising results in vitro, although very few studies have been conducted to assess the clinical impact of these agents. |
| format | Article |
| id | doaj-art-0665cdba0cb24e8688c10f1022b07b2f |
| institution | Kabale University |
| issn | 1687-4757 1687-4765 |
| language | English |
| publishDate | 2008-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | PPAR Research |
| spelling | doaj-art-0665cdba0cb24e8688c10f1022b07b2f2025-02-03T06:13:43ZengWileyPPAR Research1687-47571687-47652008-01-01200810.1155/2008/672829672829The Role of the PAX8/PPARγ Fusion Oncogene in Thyroid CancerKimberly A. Placzkowski0Honey V. Reddi1Stefan K. G. Grebe2Norman L. Eberhardt3Bryan McIver4Division of Endocrinology, Department of Medicine, Mayo Clinic & Foundation, Rochester, MN 55905, USADivision of Endocrinology, Department of Medicine, Mayo Clinic & Foundation, Rochester, MN 55905, USADepartment of Laboratory Medicine and Pathology, Mayo Clinic & Foundation, Rochester, MN 55905, USADivision of Endocrinology, Department of Medicine, Mayo Clinic & Foundation, Rochester, MN 55905, USADivision of Endocrinology, Department of Medicine, Mayo Clinic & Foundation, Rochester, MN 55905, USAThyroid cancer is uncommon and exhibits relatively low mortality rates. However, a subset of patients experience inexorable growth, metastatic spread, and mortality. Unfortunately, for these patients, there have been few significant advances in treatment during the last 50 years. While substantial advances have been made in recent years about the molecular genetic events underlying papillary thyroid cancer, the more aggressive follicular thyroid cancer remains poorly understood. The recent discovery of the PAX8/PPARγ translocation in follicular thyroid carcinoma has promoted progress in the role of PPARγ as a tumor suppressor and potential therapeutic target. The PAX8/PPARγ fusion gene appears to be an oncogene. It is most often expressed in follicular carcinomas and exerts a dominant-negative effect on wild-type PPARγ, and stimulates transcription of PAX8-responsive promoters. PPARγ agonists have shown promising results in vitro, although very few studies have been conducted to assess the clinical impact of these agents.http://dx.doi.org/10.1155/2008/672829 |
| spellingShingle | Kimberly A. Placzkowski Honey V. Reddi Stefan K. G. Grebe Norman L. Eberhardt Bryan McIver The Role of the PAX8/PPARγ Fusion Oncogene in Thyroid Cancer PPAR Research |
| title | The Role of the PAX8/PPARγ Fusion Oncogene in Thyroid Cancer |
| title_full | The Role of the PAX8/PPARγ Fusion Oncogene in Thyroid Cancer |
| title_fullStr | The Role of the PAX8/PPARγ Fusion Oncogene in Thyroid Cancer |
| title_full_unstemmed | The Role of the PAX8/PPARγ Fusion Oncogene in Thyroid Cancer |
| title_short | The Role of the PAX8/PPARγ Fusion Oncogene in Thyroid Cancer |
| title_sort | role of the pax8 pparγ fusion oncogene in thyroid cancer |
| url | http://dx.doi.org/10.1155/2008/672829 |
| work_keys_str_mv | AT kimberlyaplaczkowski theroleofthepax8ppargfusiononcogeneinthyroidcancer AT honeyvreddi theroleofthepax8ppargfusiononcogeneinthyroidcancer AT stefankggrebe theroleofthepax8ppargfusiononcogeneinthyroidcancer AT normanleberhardt theroleofthepax8ppargfusiononcogeneinthyroidcancer AT bryanmciver theroleofthepax8ppargfusiononcogeneinthyroidcancer AT kimberlyaplaczkowski roleofthepax8ppargfusiononcogeneinthyroidcancer AT honeyvreddi roleofthepax8ppargfusiononcogeneinthyroidcancer AT stefankggrebe roleofthepax8ppargfusiononcogeneinthyroidcancer AT normanleberhardt roleofthepax8ppargfusiononcogeneinthyroidcancer AT bryanmciver roleofthepax8ppargfusiononcogeneinthyroidcancer |